Initial Polish experience of Flexible 19 gauge Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration

The authors declare no financial disclosure

Abstract

Introduction: EBUS is a well established minimally invasive diagnostic tool for mediastinal and hilar lymphadenopathy. The novel ViziShot Flex 19G needle (Olympus Respiratory America, Redmond, WA, USA) was introduced in 2015 in order to improve loaded scope flexion and to obtain larger tissue samples for analysis. The aims of this study were to assess diagnostic yield of Flex 19G needles and to present endoscopist’s feedback about the endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA).

Material and methods: The Flex 19G needles were used in patients with hilar and/or mediastinal adenopathy in two Polish pulmonology centers. Cytology smears and cell blocks (CB) were prepared. The prospective analysis was performed due to collected data.

Results: Twenty two selected patients with confirmed adenopathy on chest-CT (mean age 58 ± 12) underwent EBUS-TBNA with use of Flex 19G needles. All procedures occurred to be diagnostic for smears (yield 100%). The malignancy was found in 15 cases (68.2%), and benign adenopathy in 7 (31.8%). In 12 of 14 cases of lung cancer (yield 85.7%) CB were diagnostic for immunohistochemical and molecular staining. After puncturing nodes, especially in hilar position not extensive bleeding was observed. Comparing to standard 21/22G EBUS-TBNA endoscopists underlined better flexion of loaded scope and sample adequacy and found non-significant differences in another biopsy details.

Conclusions: The first Polish experience with use of Flex 19G EBUS-TBNA needle occurs to be similar in performance with standard technique with use of 22/21G needles and presents high diagnostic yield for lung cancer diagnostics, especially when preparing CB. A safety profile of the biopsy is acceptable.

Key words: EBUS-TBNA, flex 19G needle, lung cancer, sarcoidosis, lymphadenopathy

Introduction

The role of the Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration (EBUS-TBNA) combined with Endoscopic Ultrasoundography-Guided Fine Needle Aspiration using EBUS scope (EUS-B-FNA) or EUS scope is a well established and recommended method as the first step towards minimally invasive lung cancer staging [1]. EBUS-TBNA is also successfully performed for diagnostic purposes in patients with paratracheal and peribronchial tumours [2, 3].
There is quite a lot of data presenting the usefulness of the EBUS-TBNA for diagnosing patients with benign mediastinal and/or hilar lymphadenopathy, especially those suspected of sarcoidosis [4]. The area visualised with the EBUS scope includes the upper and lower para- and retro-tracheal, subcarinal and hilar regions. Whereas the only limitation of the ultrasonographic visualisation is the outer diameter of the scope, in some cases its flexibility decreased by introducing TBNA needle into the working channel reduces the biop tic area.

The novel first generation of Flex 19G needle (Olympus Respiratory America, Redmond, WA, USA) for the EBUS-TBNA use was developed and brought to market in 2015. The main advantages of the needle claimed by the manufacturer are as follows: improved flexibility (from 45° maximal flex for scope loaded with standard 21G needle to 84° while using Flex 19G needle) (Fig. 1), enlarged inner lumen with the same outer diameter (1.9 mm) for obtaining bigger tissue samples and improved echogenicity of the needle for better visualisation on ultrasound image.

In the current paper we presented our initial experience of the first generation of Flex 19G EBUS-TBNA needle. The aim of our work was to assess diagnostic yield and to report complications associated while using the tool and to present subjective endoscopist’s feedback after its use.

Material and methods

The Flex 19G needle was used for EBUS-TBNA in 22 selected patients with enlarged hilar or mediastinal lymph nodes on CT scans for staging and diagnosis of lung cancer and for other benign lymphadenopathies. The procedure was performed by three experienced endoscopists in two Polish pulmonology centers. The Olympus EBUS scope (BF-UC180F) with 2.2 mm working channel diameter was used. After signing informed consent, all patients underwent EBUS under mild conscious sedation with the use of midazolam (2–5 mg) and fentanyl (0.025–0.1 mg) administered intravenously. Pulsoxymetric measurement for patients’ monitoring was mandatory, and oxygen supplementation provided when necessary.

EBUS-TBNA was performed with 2 to 3 needle passes in at least 2 selected areas. For cytological assessment smears and cell blocks (CB), when malignancy was suspected were prepared. After the procedure, both sampled areas (nodal stations or tumour) and endoscopist’s feedback were noted. Lymph node stations were examined in accordance to the lymph node map introduced by the International Association for the Study of Lung Cancer (IASLC) [5]. Endoscopists were asked to fill the questionnaire after finishing the procedure. Absolute and relative (comparing with standard 21/22G EBUS-TBNA) performance was assessed using the questionnaire. Endoscopists also answered questions about possible disadvantages of the new needle as shown in Table 1. Physician’s feedback was referred to flexibility of the loaded scope, facility of puncture of the targeted area, quality of the needle visualisation in the ultrasound image and the quality and amount of the obtained tissue for preparing smears.

Biopsies were assessed by experienced pathologists in both hospitals for being diagnostic, and if so, for final diagnosis. In case of non-diagnostic biopsy, other invasive procedures such as mediastinoscopy or systematic lymph node dissection during lung resection were planned to establish final diagnosis.

Results

Endoscopic procedures were performed in October and November 2015 in Endoscopy Units of Pulmonary Hospital in Zakopane (16 patients) and John Paul II Hospital in Cracow (6 patients). Twenty two selected patients with mediastinal and/or hilar lymphadenopathy underwent EBUS-TBNA with Flex 19G needle. The examined group consisted of 15 (68.2%) men and 7 (31.8%) women, aged between 32 and 80, mean 58 ± 12 years.

In 22 patients, 48 selected areas (nodal stations or tumours) were biopsied as shown in Table 2. The final diagnosis was established by EBUS-TB-
Table 1. Results of the questionnaire filled by bronchoscopists after each procedure

<table>
<thead>
<tr>
<th></th>
<th>Unacceptable</th>
<th>Acceptable</th>
<th>Worse</th>
<th>Comparable</th>
<th>Better</th>
</tr>
</thead>
<tbody>
<tr>
<td>Did the device penetrate the target?</td>
<td>1 (4.5%)</td>
<td>21 (95.5%)</td>
<td>–</td>
<td>19 (86.4%)</td>
<td>3 (13.6%)</td>
</tr>
<tr>
<td>Did the device collect adequate samples?</td>
<td>–</td>
<td>22 (100%)</td>
<td>–</td>
<td>2 (9.1%)</td>
<td>20 (90.9%)</td>
</tr>
<tr>
<td>Was the device visible during sampling?</td>
<td>–</td>
<td>22 (100%)</td>
<td>–</td>
<td>20 (90.9%)</td>
<td>2 (9.1%)</td>
</tr>
<tr>
<td>Overall impression of performance</td>
<td>–</td>
<td>22 (100%)</td>
<td>–</td>
<td>16 (72.7%)</td>
<td>6 (27.3%)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th></th>
<th>Yes</th>
<th>No</th>
</tr>
</thead>
<tbody>
<tr>
<td>Did the needle become ‘bent’ or ‘curved’?</td>
<td>–</td>
<td>22</td>
</tr>
<tr>
<td>Did the needle become excessively curved?</td>
<td>–</td>
<td>22</td>
</tr>
<tr>
<td>Did the needle become noticeably dull?</td>
<td>–</td>
<td>22</td>
</tr>
<tr>
<td>Did the needle ever snag and/or penetrate the sheath?</td>
<td>–</td>
<td>22</td>
</tr>
</tbody>
</table>

Table 2. Baseline characteristics

<table>
<thead>
<tr>
<th>Total (n)</th>
<th>22</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gender</td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>15  (68.2%)</td>
</tr>
<tr>
<td>Female</td>
<td>7   (31.8%)</td>
</tr>
<tr>
<td>Age (years)</td>
<td>58 ± 12</td>
</tr>
<tr>
<td>Final diagnosis</td>
<td></td>
</tr>
<tr>
<td>Sarcoïdosis</td>
<td>4  (18.2%)</td>
</tr>
<tr>
<td>Reactive LN</td>
<td>3   (13.6%)</td>
</tr>
<tr>
<td>Lung cancer</td>
<td>14  (63.6%)</td>
</tr>
<tr>
<td>Adenocarcinoma</td>
<td>5  (22.7%)</td>
</tr>
<tr>
<td>Squamous cell carcinoma</td>
<td>4  (18.2%)</td>
</tr>
<tr>
<td>Small cell lung cancer</td>
<td>4   (18.2%)</td>
</tr>
<tr>
<td>Non-small cell lung cancer</td>
<td>1   (4.5%)</td>
</tr>
<tr>
<td>Clear cell adenocarcinoma</td>
<td>1  (4.5%)</td>
</tr>
<tr>
<td>Lymph nodes biopsied</td>
<td>48</td>
</tr>
<tr>
<td>4R</td>
<td>7</td>
</tr>
<tr>
<td>4L</td>
<td>6</td>
</tr>
<tr>
<td>7</td>
<td>15</td>
</tr>
<tr>
<td>10R</td>
<td>4</td>
</tr>
<tr>
<td>10L</td>
<td>2</td>
</tr>
<tr>
<td>11R</td>
<td>3</td>
</tr>
<tr>
<td>11L</td>
<td>4</td>
</tr>
<tr>
<td>Tumor</td>
<td>7</td>
</tr>
</tbody>
</table>

Table 3. Diagnostic yield of smears and cell blocks (CB)

<table>
<thead>
<tr>
<th>Final diagnosis</th>
<th>Smears n = 22</th>
<th>CB n = 15</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>22/22 (100%)</td>
<td>13/15 (86.7%)</td>
</tr>
<tr>
<td>Sarcoïdosis</td>
<td>4/4 (100%)</td>
<td>–</td>
</tr>
<tr>
<td>Reactive LN</td>
<td>3/3 (100%)</td>
<td>–</td>
</tr>
<tr>
<td>Lung cancer</td>
<td>14/14 (100%)</td>
<td>12/14 (85.7%)</td>
</tr>
<tr>
<td>Clear cell adenocarcinoma</td>
<td>1/1 (100%)</td>
<td>1/1 (100%)</td>
</tr>
</tbody>
</table>

CB — cell blocks

NA with the use of the Flex 19G needles in all cases. There were 7 benign lymphadenopathies (4 sarcoïdosis and 3 reactive lymph nodes). Malignancy was found in 15 cases (14 primary lung cancers and 1 metastatic clear cell cancer of the kidney). If needed, tissue material obtained by needle biopsy was adequate for immunocytochemical (IHC) staining and molecular genotyping (EGFR mutation testing). Smears were prepared in all 22 patients and all of them were found to be diagnostic (yield 100%).

Cell blocks (CB) were prepared in 15 patients suspected of malignancy and were diagnostic in 13 of them (86.7%) (Table 3).

As shown in Table 1, absolute performance was acceptable regarding penetration of the target (95.5%), collecting adequate sample (100%), visibility of the needle in ultrasonography (100%) and overall impression of the procedure (100%). Relative performance was assessed as comparable in the area of target penetration (86.4%), needle visibility (90.9%) and overall impression of the procedure (72.7%); and was found to be better in obtaining adequate samples for preparing smears (90.9%). No device dependent complications were reported.

Improved flexibility of the loaded scope measured in our sites was about 21 degrees (from 57° while using standard 22G needle to 78° with new device) (Figs 2, 3).
No severe complications were observed except for the subject who presented bleeding after biopsy of the right hilar nodes, controlled with cooled saline.

**Discussion**

In the first Polish experience, EBUS-TBNA with the use of the Flex 19G needles showed very high diagnostic yield for malignancy and sarcoidosis. But the small number of selected patients must be underlined regarding reported in the literature diagnostic yield of this procedure in lung cancer staging — 89%, and in mediastinal lymphadenopathy — 92% [6, 7].

The Canadian experience of the device also suggests high diagnostic yield in different lymphadenopathies [8].

The endoscopist’s feedback shown in our work corresponds with the results presented by Szczaniecka et al. [9] at the European Respiratory Society Congress in London (September 2016).

The tissue sample obtained with the needle occurred to be adequate for cytological, IHC and molecular (EGFR) lung cancer typing, which is in accordance with the literature on the topic [10–12]. The quality of CB samples are highly promising especially for ALK, ROS1 and PD-L1 typing, when bigger samples are needed. A complication rate observed in our study was comparable with the standard EBUS-TBNA [1, 2, 6–8].

**Conclusions**

In our experience, Flex 19G EBUS-TBNA needle occurs to be similar in performance to standard technique using 22/21G needles, and presents high diagnostic yield for lung cancer diagnostics, especially for preparing CB. A significantly better flexion of the loaded scope allows the access for the bigger biotic area, hence better sample adequacy can be achieved. A safety profile of the biopsy is acceptable.

**Conflict of interest**

The authors declare no conflict of interest.

**References:**


